Results 171 to 180 of about 72,056 (263)
Diabetes, Obesity and Metabolism, EarlyView.Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley +1 more source
Evidence-based strategies of exercise and nutrition in sarcopenia care in liver cirrhosis patients. [PDF]
Hepatobiliary Surg NutrZhang J, Qiu F.
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract The clinical management of metabolic dysfunction‐associated steatotic liver disease (MASLD) and metabolic dysfunction‐associated steatohepatitis (MASH) is undergoing rapid evolution, driven by advances in noninvasive diagnostics and the recent approval of liver‐directed therapies.
Fernando Bril
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) represents a key hepatic manifestation of obesity and systemic metabolic dysfunction and is a leading cause of chronic liver disease worldwide. Obesity‐driven mechanisms, including adipose tissue dysfunction, insulin resistance and increased free fatty acid flux to the liver ...
Michael Romanos +4 more
wiley +1 more source
Risk factors for significant hepatic fibrosis in alcoholic liver disease and construction of a nomogram prediction model. [PDF]
BMC GastroenterolJin M, Zhou J, He DM, Chen FL, Li HW.
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Excess adiposity and obesity are increasingly prevalent, with incidence rising in many parts of the world; both trigger a state of metabo‐inflammation in adipose tissue, creating a systemic milieu characterised by insulin resistance and pro‐inflammatory and fibrogenic states. Along with systemic inflammatory cues, perturbations in systemic and
Mirjana Grocic +2 more
wiley +1 more source
Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley +1 more source
Association between duration of alcohol consumption and risk of hematemesis in patients with alcoholic cirrhosis complicated by esophagogastric variceal bleeding: a case-control study. [PDF]
BMC GastroenterolDing S, Lu S, Cui L, Li J, Qin X, Liu X.
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The burden of chronic liver disease (CLD) is increasing. This study aims to identify protein markers for CLD and its progression, and develop a protein‐based risk prediction model. Materials and Methods We used proteome‐wide Mendelian randomization (MR), Bayesian colocalization and summary‐data‐based MR with proteomic data from deCODE ...
Xinxuan Li +9 more
wiley +1 more source